Abstract Splenic marginal zone lymphoma (SMZL) and splenic diffuse large B-cell lymphoma (DLBCL) are the most common types of lymphomas involving the spleen. Geographic variation in hepatitis C virus (HCV) seroprevalence is characteristic of splenic lymphomas. In Italy, HCV seroprevalence was higher in patients with SMZL and splenic DLBCL than in patients with all types of lymphoma. In Japan, HCV seroprevalence was higher in patients with splenic DLBCL than in patients with all types of lymphoma; however, HCV seroprevalence in patients with SMZL was similar to that in patients with all types of lymphoma. In this study, clinicopathological data of 74 splenic lymphoma cases between 1988 and 2011 collected from the Department of Pathology at National Taiwan University Hospital were analyzed. Serology for HCV infection was available for 41 cases. Splenic DLBCL and SMZL accounted for 36% (n Z 27) and 42% (n Z 31) of splenic lymphomas, respectively. Microscopically, most cases of DLBCL (26/27) presented with circumscribed tumor and most cases of SMZL (28/31) presented with white pulp expansion. HCV seroprevalence in patients with DLBCL and SMZL was 44% and 10%, respectively (7/16 vs. 2/20, p Z 0.020). The pattern identified in this study is closer to that in Japan than in Italy. HCV seroprevalence in patients with early-stage (I/II) and late-stage (III/IV) DLBCL was 100% and 10%, respectively (6/6 vs. 1/10, p < 0.001). Early-stage DLBCL is clinically considered a form of primary splenic lymphoma rather than a systemic lymphoma with splenic involvement. High HCV seroprevalence in patients with early-stage DLBCL suggests a role of HCV in the pathogenesis of primary DLBCL.
Introduction
Splenic lymphomas are heterogeneous. They may be primary, arising from the spleen, or secondary, involving the spleen as part of systemic dissemination of a lymphoma that arises elsewhere. Primary splenic lymphoma is rare and accounts for <1% of all lymphoma cases [1] .
Splenic lymphomas may involve only the spleen (stage I) or extend to the regional lymph nodes (LNs) (stage II). They may also have more distant LN (stage III) or bone marrow (BM) involvement (stage IV). Stage I lymphomas are primary, stage II lymphomas are most often primary, and stage III and IV lymphomas are most often secondary.
Among splenic lymphomas, diffuse large B-cell lymphoma (DLBCL) and splenic marginal zone lymphoma (SMZL) are two of the most common histological types, accounting for approximately 33% and 8% of splenic lymphomas, respectively [2] . DLBCL of the spleen may present in the early (I/II) or late (III/IV) stages. Biological differences between early-and late-stage DLBCL are still unclear. BM involvement is usually characteristic of SMZL, but LN involvement is relatively uncommon [3] .
The association between hepatitis C virus (HCV) infection and malignant lymphoma is well documented. The prevalence rate of this association ranges from 2.8% to 19.6% [4, 5] and has been reported as 11% in Taiwan [6] . This association is due to a high infection rate in lymphomas in extranodal sites [7] , such as SMZL. For example, the prevalence of HCV infection in patients with SMZL is 35% in Italy [8] . Interestingly, in a Japanese series of studies, the prevalence of HCV infection was found to be very high in patients with splenic DLBCL (51.7%) [9] . The data suggest that splenic DLBCL may also be associated with HCV infection. However, data on HCV infection in splenic lymphoma in Taiwan are limited.
In this study, clinicopathological pictures of 74 splenic lymphomas were investigated. This is the only large series of splenic lymphoma cases in Taiwan. In addition to hematological factors, anti-HCV serology and associated clinical data were reviewed. In a subgroup comparison, early-stage splenic DLBCL was found to be highly associated with HCV infection. Because early-stage splenic lymphomas are considered to be primary splenic lymphomas, this finding suggests a role of HCV in the pathogenesis of primary splenic DLBCL.
Materials and methods

Case selection
Among 2593 pathological spleen specimens in the archives (from 1988 to 2011) of the Department of Pathology in National Taiwan University Hospital, 97 cases had a diagnosis of lymphoma or hematological malignancy. Fourteen cases of lymphoma with incomplete staging workup and nine cases of myeloid neoplasms were excluded. Thus, 74 cases of splenic lymphoma were included in this retrospective study. Slides of spleen, BM, LN, and extranodal sites were reviewed to confirm the diagnosis according to the World Health Organization classification.
Clinical data
Data concerning age at splenectomy, sex, and underlying disease were obtained from the medical records. Laboratory data, such as lymphocyte count in peripheral blood, serum lactate dehydrogenase (LDH), and immunofixation electrophoresis of urine and serum specimens, were extracted from the medical records. Staging workup for lymphoma included physical examination, computed tomography (CT), and pathological examinations of the BM and spleen.
Hepatitis-associated data, including serum anti-HCV antibody, HCV viral RNA, hepatitis B surface antigen (HBsAg), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), g-glutamyl transpeptidase (g-GT), total and direct bilirubin, prothrombin time (PT), albumin, and history of interferon or ribavirin treatment, liver cirrhosis, and hepatocellular carcinoma (HCC) were reviewed.
By the Ann Arbor staging system, splenic lymphomas were divided into early (I/II) and late (III/IV) stages. Stage I diseases involved only the spleen. Stage II diseases involved the spleen and subdiaphragmatic LN. Stage III diseases involved the spleen and LN on both sides of the diaphragm. Stage IV diseases involved the spleen, BM, and/or other extranodal sites.
Various treatments may follow splenectomy: oral chemotherapy only, rituximab without intravenous chemotherapy, intravenous chemotherapy, or observation only. Treatment responses, such as complete remission, partial remission, stable disease, or progressive disease, were evaluated by physical examination, CT, lymphocyte count, and LDH testing, according to the criteria of the International Working Group.
Statistical analysis
Two-sample comparisons were analyzed using Student t test for continuous data, the Chi-square test, or Fischer's exact test for categorical data. Survival curves were analyzed by the KaplaneMeier method and compared using the log-rank test.
Results
Pathological features
In the medical records evaluated in this study, 69 B-cell lymphomas, three T-cell lymphomas, one lymphoblastic lymphoma, and one unspecified high-grade lymphoma were examined. SMZL and DLBCL were the most common histological types, accounting for 42% and 36% of all splenic lymphomas, respectively. Splenectomy was rarely performed in lymphomas with preferential nodal presentation, such as Hodgkin's lymphoma and follicular lymphoma.
Circumscribed tumors were present in 26 of the 27 cases of DLBCL. The other case showed diffuse infiltration of the splenic parenchyma. Typical cytology and immunophenotype of DLBCL was evident in all cases. In one case, involvement of accessory spleen and hilar LN was observed, the morphology of which was similar to that of the splenic main tumor. Among the seven cases of DLBCL with BM involvement, paratrabecular infiltration was noted in six and interstitial infiltration in one.
White pulp expansion was present in 28 of 31 cases of SMZL, and three cases presented with mixed white pulp and red pulp diseases. No expression of CD5, CD10, or cyclin D1 was observed in any case. Accessory spleen involvement was noted in five cases of SMZL. In these cases, morphology was nearly identical to that in the spleen. Hilar LN involvement was observed in eight cases of SMZL. Effaced architecture with a nodular pattern was evident in all of these cases, and patent sinuses were noted in four of them. Of the 26 cases with BM involvement, paratrabecular infiltration was evident in 15, nonparatrabecular nodular aggregates were present in six, diffuse infiltration was noted in two, and interstitial infiltration was noted in three.
Clinical data
In our series of 74 cases of splenic lymphoma, the average age was 57 years and male-to-female ratio was 1.31. Details of histology, stage, and anti-HCV status in these patients are shown in Table 1 . Note that 81% (60/74) of cases were stage III or IV.
Among the 74 patients, data about the anti-HCV antibody and HBsAg were available for 41 (55%) and 40 (54%) patients, respectively. Of the 41 patients, 11 (27%) were tested positive for the anti-HCV antibody and five for the serum HCV viral RNA. Of the 40 patients, 13 (33%) were tested positive for HBsAg.
Among the 11 HCV-positive patients, the average values of AST, ALT, ALP, and g-GT were 65 (AE61) U/L (reference range: <37 U/L in males, <31 U/L in females), 65 (AE60) U/L (reference range: <41 U/L in males, <31 U/L in females), 214 (AE96) U/L (reference range: 60e220 U/L), and 96 (AE83) U/L (reference range: <52 U/L), respectively. Total and direct bilirubin, PT, and albumin levels were normal in all patients. No patient had received interferon or ribavirin therapy for HCV. One patient had a history of Child A liver cirrhosis, but none had a history of HCC.
Clinicopathological data of primary splenic lymphomas
After exclusion of cases with BM, LN, and other extrasplenic involvement [10] , only six primary splenic lymphomas were found, including three cases of DLBCL, two cases of SMZL, and one unspecified high-grade lymphoma. Representative images of these cases are shown in Fig. 1 . All three cases of primary DLBCL of the spleen were HCV positive, but two of primary SMZL were HCV negative.
Chemotherapy was administered in two cases of DLBCL. The other case of DLBCL received no additional therapy after splenectomy. All three cases were disease free, with a follow-up course of 4e119 months.
One SMZL case had stable disease for 48 months with no additional treatment after splenectomy. In the other SMZL case (a 43-year-old woman), mixed white pulp and red pulp disease was evident and paraneoplastic pemphigus was observed clinically. Despite chemotherapy, the woman died of acute pancreatitis 10 months later.
An unusual pattern of red pulp disease accompanied by hemophagocytosis was observed in the final case (a 37-year-old woman) of unspecified high-grade lymphoma. Chemotherapy was administered, but this patient died of severe infection 8 months later.
Comparison of DLBCL and SMZL
Clinical features of DLBCL and SMZL, the two most common types of splenic lymphoma, are compared in Table 2 . HCV seroprevalence was higher in patients with splenic DLBCL than in those with SMZL (44% vs. 10%, p Z 0.020). In Taiwan, HCV seroprevalence in patients with splenic DLBCL was higher than and that in patients with SMZL was similar to the overall HCV prevalence rate in patients with lymphoma (11%) [6] . This finding suggests an association between HCV infection and splenic lymphoma, particularly splenic DLBCL.
Significant differences were observed between splenic DLBCL and SMZL at the sites of involvement (p < 0.001). BM involvement was higher in SMZL cases than in DLBCL cases CLL Z chronic lymphocytic leukemia; DLBCL Z diffuse large B-cell lymphoma; HCV Z hepatitis C virus; NA Z not available; NOS Z not otherwise specified; SMZL Z splenic marginal zone lymphoma.
(84% vs. 26%, respectively). Peripheral blood lymphocytosis was higher in SMZL cases than in DLBCL cases (37% vs. 8%, respectively, p Z 0.016). Extranodal involvement was observed more often in DLBCL cases than in SMZL cases (44% vs. 10%, p Z 0.003).
Different treatments were used for splenic DLBCL and SMZL. Chemotherapy was administered in most cases of splenic DLBCL (96%) after splenectomy. However, chemotherapy was administered only in approximately half (55%) of the SMZL cases. Approximately one-third (32%) of patients with SMZL received no additional treatment after splenectomy. Treatment response and survival rates also differed between DLBCL and SMZL cases, but the number of cases was too small to achieve statistical significance. Indolent course and good survival (2-year survival: 93%) were observed in the SMZL cases. Most patients (52%) had stable disease without remission or progression. However, treatment response was variable in DLBCL cases and the 2-year survival rate was only 56%.
Comparison of early-and late-stage DLBCL
To identify factors contributing to HCV infection, early-and late-stage DLBCL cases were compared (Table 3) . HCV seroprevalence in patients with early-stage splenic DLBCL was much higher than that in patients with late-stage splenic DLBCL (100% vs. 10%, p < 0.001). However, HCV seroprevalence in patients with late-stage splenic DLBCL was similar to that in patients with SMZL (10%) and to the overall prevalence of HCV infection in patients with lymphoma in Taiwan (11%) [6] .
Ten early-stage DLBCL cases were recorded; of these, the status of HCV infection was known in six cases, all of whom were HCV positive. Primary splenic lymphoma was identified in three of these cases. Due to abdominal LN involvement, the other three cases also presumably had primary splenic lymphomas [10] . Therefore, the results of this study demonstrate that HCV infection may be associated with the pathogenesis of primary DLBCL of the spleen.
For both early-and late-stage DLBCL, most cases received chemotherapy after splenectomy (90% and 100%, respectively). Not surprisingly, good treatment response and better survival rates (2-year survival: 90%) were evident in the early-stage DLBCL cases. On the other hand, variable treatment response and lower survival rates (2-year survival: 42%) were recorded in late-stage DLBCL cases. For survival rate, the number of cases was too small to achieve statistical significance. Age Z age at splenectomy; BMþ Z bone marrow involvement; BMe Z no bone marrow involvement; DLBCL Z diffuse large Bcell lymphoma; HBsAg Z hepatitis B surface antigen; HCV Z hepatitis C virus; IV Z intravenous; LDH Z lactate dehydrogenase; LNþ Z lymph node involvement; LNe Z no lymph node involvement.
Discussion
The country-wise prevalence of HCV infection is summarized in Table 4 [4e6,8,9,11e19]. With some variation, the prevalence of HCV infection was higher in patients with lymphoma than in the general population of most geographic areas. The HCV seroprevalence rate varied widely. It accounted for approximately 35% and 10% of patients with SMZL in Italy and in Japan, respectively [8, 9] . The prevalence of splenic DLBCL varied from approximately 50% in Japan to approximately 60% in Europe [8, 9, 18] . Data on HCV infection in Taiwanese lymphoma patients are limited. In a study of the association of HCV infection and malignant lymphoma in Taiwan, Chuang et al. [6] reported that 11% of lymphoma patients were HCV positive. In that series, two cases of SMZL were examined and both were found to be HCV positive. No data on splenic DLBCL in Taiwan have ever been reported. Although the number of cases was small, one of the largest series in Asia was investigated in this study. HCV seroprevalence in patients with SMZL and splenic DLBCL was 10% (2/20) and 44% (7/16), respectively. This pattern is similar to that identified in a study based in Japan (SMZL: approximately 10%; splenic DLBCL: approximately 50%) but not to that found in Italy (SMZL: approximately 35%; splenic DLBCL: approximately 60%). Patterns of HCV infection may differ between East Asia and Europe. Larger studies involving more data are required to support this hypothesis.
Identification of the primary tumor site is more difficult for lymphomas than for solid tumors. Splenic involvement is frequently observed in late-stage lymphomas. The definition of primary splenic DLBCL is ambiguous in the literature. In this study, strict criteria were used to define primary splenic lymphoma [1, 10] . Cases with spleen involvement only (stage I) were considered as primary splenic lymphomas, and cases with extension to abdominal LN (stage II) were presumed to be primary splenic lymphomas. HCV seroprevalence in patients with earlystage (I/II) splenic DLBCL was found to be extremely high (6/6, 100%). HCV seroprevalence in patients with late-stage (III/IV) splenic DLBCL (1/10, 10%) was similar to that in patients with all types of lymphoma. This finding suggests a role of HCV in the pathogenesis of primary splenic DLBCL.
HCV infection may cause lymphoma through several mechanisms. In HCV infection, chronic antigen stimulation results in lymphocyte proliferation. This proliferation may lead to lymphoma because the immunoglobulin gene repertoire is similar in chronic HCV infection, cryoglobulinemia, and HCV-associated lymphomas [20] . In addition, the HCVencoded E2 protein may interact with CD81 to induce B-cell activation, reduce apoptosis, and increase double-strand DNA break and hypermutation [21e23] . Finally, HCV may infect lymphocytes directly [24] . Lymphoma cell lines infected with HCV have been shown to increase cell proliferation and decrease apoptotic activity [25, 26] .
Despite these data, the role of HCV infection in splenic DLBCL is largely unknown. Although viral RNA and proteins are present in splenic DLBCL [27] , the immunoglobulin gene repertoire and E2eCD81 interactions have not been characterized in it.
Unlike SMZL, cases of splenic DLBCL, particularly those in the early stages, rarely involve peripheral blood, which makes the study of these cases difficult. First, specimens of splenic DLBCL may be obtained by invasive procedures only. Because of the low number of DLBCL cases and the invasiveness of these procedures, specimens are limited. Second, precancerous lesions such as peripheral blood oligoclonal and monoclonal lymphocytosis are not characteristic of splenic DLBCL. No stepwise model of the pathogenesis of splenic DLBCL has been outlined. Moreover, the benign counterpart of splenic DLBCL is not well recognized histologically in the normal spleen.
Current knowledge of HCV-induced B-cell proliferation is based on liver and peripheral blood studies [28, 29] . Hepatosplenomegaly is a common manifestation in hematological diseases, which suggests that liver and spleen may share certain similarities in lymphoma cell homing. However, the similarities or differences regarding lymphocytes and microenvironment between these two organs are unclear. It is questionable whether HCV induces B-cell proliferation in the spleen in the same manner as in the liver.
Complete remission of HCV-positive SMZL after ribavirin and interferon treatment has been reported [30] . Only two cases of HCV-positive SMZL were evaluated in our series. The benefits of anti-HCV treatment in the clinical course of SMZL require further evaluation. This study is the only investigation of a large series of splenic lymphoma patients in Taiwan. Six rare cases of primary splenic lymphoma were reported here. The prevalence of HCV infection in patients with early-stage splenic DLBCL, which were presumed to be primary in this study, is 100% in Taiwan. The prevalence pattern in Taiwan (10% for SMZL and 44% for DLBCL) is similar to that in Japan (about 10% for SMZL and about 50% for DLBCL) but differs from that in Italy (about 35% for SMZL and about 60% for DLBCL). The higher HCV infection rate in DLBCL cases in Taiwan and Japan suggests differences in the pathogenesis of splenic lymphoma in East Asia versus Europe. The molecular mechanism of HCV in the pathogenesis of primary DLBCL of the spleen requires further study.
